stockrow
Friday 6 November 2026
Export MMED’s income statement to Excel — free account
MiniMed Group, Inc.
MMED Healthcare Medical Instruments & Supplies
MiniMed Group, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $3.1 billion, up 14.3% from fiscal 2025.
18.23
1.06
−5.50%
Follow MMED
Alert me
MiniMed Group, Inc. (MMED) Net margin
MiniMed Group, Inc.'s net margin over the twelve months to 31 July 2026 was −4.86%, up 5.9 percentage points from fiscal 2026 (−10.7%). That is below the Medical Instruments & Supplies industry median of 0.00% and below the Healthcare sector median of 0.00%.
Net margin, annual
Embed this chart
Annual newest first
| Period | Net margin | Change (points) |
|---|---|---|
| FY2026 | −10.7% | (2.89) |
| FY2025 | −7.85% | (3.31) |
| FY2024 | −4.54% | — |
Quarterly newest first
| Period | Net margin | Change (points) |
|---|---|---|
| Jul 2026 | 0.00% | 15.06 |
| Jan 2026 | −15.1% | (12.43) |
| Jul 2025 | −2.63% | (1.17) |
| Jan 2025 | −1.46% | — |
Net margin against peers
| Company | Net margin |
|---|---|
| NVST Envista Holdings Corporation compare | 22.0% |
| STVN Stevanato Group S.p.A. compare | 11.2% |
| MMSI Merit Medical Systems, Inc. compare | 9.94% |
| ICUI ICU Medical, Inc. compare | 2.76% |
| ATRC AtriCure, Inc. compare | 2.52% |
| BLCO Bausch + Lomb Corporation compare | −2.05% |
| MMED MiniMed Group, Inc. | −4.86% |
| TFX Teleflex Incorporated compare | −45.8% |
| PLSE Pulse Biosciences, Inc compare | −5,609.4% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 1.06% |
What Net margin is
Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.
Net Income Allotted to Shareholders ÷ Revenue
More on MMED
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement